LGND Q3 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+36.8% YoY

Gross Profit

$44M96.8% margin

Operating Income

$23M51.2% margin

Net Income

$67M147.5% margin

EPS (Diluted)

$2.80

QoQ Revenue Growth

-49.3%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$1.4B

Stockholders' Equity

$700M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$33M	+36.8%
Gross Profit	$44M	$31M	+42.6%
Operating Income	$23M	$16M	+41.6%
Net Income	$67M	$8M	+699.5%

Revenue Segments

MaterialSalesCaptisolMember

$7M74%

LicenseFeesMilestonesandProductOtherMember

$3M26%